The recent therapeutic success of two dual CDK4/6 inhibitors, palbociclib [19] and ribociclib [20], approved by the FDA for the treatment of patients with estrogen receptor (ER)-positive and HER2-negative advanced breast cancer, respectively, has renewed interest in the therapeutic potential of small-molecule inhibitors for CDKs. The gene discussed is ESR1; the disease is breast carcinoma.